104 related articles for article (PubMed ID: 32036219)
21. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
[TBL] [Abstract][Full Text] [Related]
22. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
23. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
24. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism.
Li B; Zhang J; Su Y; Hou Y; Wang Z; Zhao L; Sun S; Fu H
Mol Med Rep; 2019 Oct; 20(4):3793-3801. PubMed ID: 31485626
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
27. miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells.
Gu S; Lai Y; Chen H; Liu Y; Zhang Z
Sci Rep; 2017 Sep; 7(1):12155. PubMed ID: 28939896
[TBL] [Abstract][Full Text] [Related]
28. Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells.
Han X; Chen L; Hu Z; Chen L; Sun P; Wang Y; Liu Y
J Proteomics; 2021 Apr; 237():104122. PubMed ID: 33561557
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma.
Zhao M; Zhang Y; Zhang H; Wang S; Zhang M; Chen X; Wang H; Zeng G; Chen X; Liu G; Zhou C
Lung Cancer; 2015 Feb; 87(2):98-106. PubMed ID: 25512094
[TBL] [Abstract][Full Text] [Related]
30. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
31. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
32. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic non-coding RNA NEAT1 promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT pathway.
Xiong W; Huang C; Deng H; Jian C; Zen C; Ye K; Zhong Z; Zhao X; Zhu L
Int J Biochem Cell Biol; 2018 Jan; 94():125-132. PubMed ID: 29225160
[TBL] [Abstract][Full Text] [Related]
34. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Cui J; Zhang Y; Su D; Li T; Li Y
Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610
[TBL] [Abstract][Full Text] [Related]
36. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
37. Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis.
Duan W; Liu W; Xia S; Zhou Y; Tang M; Xu M; Lin M; Li X; Wang Q
J Transl Med; 2023 Aug; 21(1):547. PubMed ID: 37587486
[TBL] [Abstract][Full Text] [Related]
38. Pemetrexed induces G1 phase arrest and apoptosis through inhibiting Akt activation in human non small lung cancer cell line A549.
Wu DM; Zhang P; Xu GC; Tong AP; Zhou C; Lang JY; Wang CT
Asian Pac J Cancer Prev; 2015; 16(4):1507-13. PubMed ID: 25743822
[TBL] [Abstract][Full Text] [Related]
39. A novel lncRNA-hidden polypeptide regulates malignant phenotypes and pemetrexed sensitivity in A549 pulmonary adenocarcinoma cells.
Han X; Chen L; Sun P; Wang X; Zhao Q; Liao L; Lou D; Zhou N; Wang Y
Amino Acids; 2024 Feb; 56(1):15. PubMed ID: 38351332
[TBL] [Abstract][Full Text] [Related]
40. Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells.
Liu Y; Huber RM; Kiefl R; Tufman A; Kauffmann-Guerrero D
Anticancer Res; 2020 Mar; 40(3):1451-1458. PubMed ID: 32132042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
